M. Tejedor et al., MITOMYCIN, CISPLATIN, AND VINDESINE FOLLOWED BY RADIOTHERAPY COMBINEDWITH CISPLATIN IN STAGE-III NONSMALL CELL LUNG-CANCER - LONG-TERM RESULTS, International journal of radiation oncology, biology, physics, 31(4), 1995, pp. 813-818
Citations number
24
Categorie Soggetti
Oncology,"Radiology,Nuclear Medicine & Medical Imaging
Purpose: To assess the tolerance, response rate, pattern of failure, a
nd long-term survival of patients with unresectable nonsmall cell lung
cancer treated with one cycle of induction chemotherapy followed by c
oncurrent cisplatin and radiotherapy. Methods and Materials: From 1986
to 1988, 45 patients with histologically proven nonsmall cell lung ca
ncer clinical Stage III (29 IIIA and 16 IIIB) were included in this st
udy. Patients received one cycle of Mitomycin C 10 mg/m(2) day 1, Cisp
latin 120 mg/m(2) day 1, and Vindesine 3 mg/m(2) days 1, 8, 15, and 22
, by i.v. bolus injection. Radiotherapy was started within 4-6 weeks a
fter completion of chemotherapy, with a total tumor dose of 60 Gy, at
2 Gy/day. Cisplatin, 20 mg/m(2)/day by i.v. continous infusion was adm
inistered for days 1-5 of radiation treatment. Results: The main toxic
acute effects were nausea-vomiting grade 1-3 in 38 patients (85%). Te
n patients (22%) developed esophagitis grade 3. Leukopenia grade 1-2 w
as observed in 18 patients (40%), grade 3 in 12 (27%), and grade 4 in
4 (9%). Three patients (6.6%) died by granulocytopenia and sepsis. A b
ronchoscopic proven complete response was achieved in 9 patients (21.5
%) and partial response in 28 patients (67%). With a minimum follow-up
of 65 months, overall median survival was 13 months, 2-year survival
was 21%, and 5-year survival was 7%, with no statistical difference be
tween Stage IIIA and IIIB. Median survival of patients with complete r
esponse was 23.2 months, and 5-year survival was 33%. Conclusion: This
treatment scheme produced a severe toxicity and in spite of a high re
sponse rate, longterm survival is poor, similar to previous studies wi
th radiotherapy alone.